本帖最后由 老马 于 2012-1-13 21:20 编辑 % z0 b3 v% R+ |, A6 W
- F# r. P) A$ U爱必妥和阿瓦斯丁的比较7 s8 T3 b$ [* ]4 j/ Y
. g, D6 e( [8 k& P3 i2 t0 n
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 c: w' m7 V; ]! t3 Z0 U
+ x- u# T( T! H" r5 S1 @
8 J. n- Q+ A" s# j
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& o8 S$ U7 c% R9 y- U3 v( b
==================================================
. m3 q2 @7 u( h# JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! z* u) x r2 U! W
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: Z3 k& @, h. m8 u; v$ yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& d; {! E* I! e% [3 P7 f+ ~
|